Follow-on Biologics in the EU & US

| 01 January 2008

Global regulatory agencies are working hard to facilitate bringing copies of well-known medicinal biologics to market. Three key factors drive this process:

  • technological advancements permitting better characterization and testing of protein-based biologic products
  • patent expiration on many biologics in the EU and US
  • escalating healthcare costs


© 2023 Regulatory Affairs Professionals Society.

Discover more of what matters to you

No taxonomy